Containing Polysaccharide (e.g., Sugar, Etc.) Patents (Class 424/479)
-
Patent number: 8562979Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: GrantFiled: February 2, 2011Date of Patent: October 22, 2013Assignee: Aptalis Pharma LimitedInventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
-
Patent number: 8545890Abstract: The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.Type: GrantFiled: November 14, 2008Date of Patent: October 1, 2013Assignee: Rubicon Research Private LimitedInventors: Pratibha Pilgaonkar, Maharukh Rustomjee, Anilkumar Gandhi, Pradnya M. Bagde
-
Patent number: 8541421Abstract: The present invention provides, in part, substituted thieno[2,3-d]pyrimidines and methods of contacting compositions with such compounds to enhance the sweet taste of said compositions.Type: GrantFiled: March 18, 2011Date of Patent: September 24, 2013Assignee: Senomyx Inc.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Publication number: 20130236546Abstract: The invention relates to an extract made of thyme (Thymus L.) in combination with primrose (Primula veris) or ivy (Hedera helix) for the prophylaxis and treatment of chronic obstructive pulmonary diseases (COPD) and to a corresponding medicinal product and the use thereof.Type: ApplicationFiled: May 30, 2011Publication date: September 12, 2013Applicant: Bionorica SEInventors: Michael Popp, Elena Lashina
-
Publication number: 20130230592Abstract: A composition for use in preventing and/or treating and/or reducing organic, including symptomatic, mental disorders, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least one vitamin selected from vitamin B6, folic acid, vitamin B12, vitamin E, and/or vitamin D, at least one mineral which is selenium and/or zinc, optionally other vitamins, and optionally a polyphenolic plant extract with antioxidant properties.Type: ApplicationFiled: April 12, 2013Publication date: September 5, 2013Inventors: Christian TERREAUX, Eleonora HOMBERGER, Burkhard KRIWET, Anne ECKERT
-
Patent number: 8518446Abstract: The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.Type: GrantFiled: November 5, 2010Date of Patent: August 27, 2013Assignee: Wyeth LLCInventors: Muhammad Ashraf, Mainuddin Mahmud, Chimanlall Goolcharran, Krishnendu Ghosh, Arwinder Singh Nagi
-
Patent number: 8512747Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: GrantFiled: November 22, 2011Date of Patent: August 20, 2013Assignee: Orexo ABInventors: Anders Pettersson, Christer Nystrom
-
Publication number: 20130202703Abstract: Provided is a method for producing a gardenia blue pigment resistant to discoloration which may occur in colored sugar-coated food or pharmaceutical products. The method for producing such a gardenia blue pigment comprises performing membrane separation using a membrane (for example, an ultrafiltration membrane) with a molecular weight cut-off of 3000 Da or larger for removal of low-molecular compounds from a solution resulting from ?-glucosidase treatment of an iridoid glycoside (for example, geniposide etc.) in the presence of a protein hydrolysate (for example, a casein protein hydrolysate), the iridoid glycoside being obtainable by extraction from fruits of Gardenia jasminoides (Rubiaceae). Also provided is a sugar-coated food or pharmaceutical product (for example, a sugar-coated tablet, a sugar-coated chewing gum, etc.) having a sugar-coating layer colored with the gardenia blue pigment obtainable by the above-described method.Type: ApplicationFiled: September 7, 2011Publication date: August 8, 2013Inventor: Shin Sadano
-
Patent number: 8454996Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: GrantFiled: November 22, 2011Date of Patent: June 4, 2013Assignee: Orexo ABInventors: Anders Pettersson, Christer Nystrom
-
Publication number: 20130115285Abstract: An enteric coating composition including about 0.01% to about 10% resin and about 0.01% to about 10% polymer. The enteric coating composition may be applied to a substrate, such as a pharmaceutical, nutraceutical, fruit, vegetable, agricultural product, or industrial product, to form an enteric coating on the substrate. Also provided is a multiple-component system having a first component including a resin and a second component including a polymer, wherein mixing the first component and the second component forms an enteric coating composition having about 0.01% to about 10% resin and about 0.01% to about 10% polymer. Methods for coating a substrate with the enteric coating compositions are also provided.Type: ApplicationFiled: February 12, 2011Publication date: May 9, 2013Inventors: Eric H. Van Ness, Beverly A. Schad, Thomas C. Riley, Brian K. Cheng
-
Publication number: 20130115291Abstract: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.Type: ApplicationFiled: April 28, 2011Publication date: May 9, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masafumi Misaki, Yuki Tsushima, Masahiro Niwa
-
Publication number: 20130115286Abstract: Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.Type: ApplicationFiled: July 13, 2011Publication date: May 9, 2013Inventors: Mario Brufani, Bianca Maria Lagrasta, Rolando Marzella, Ilaria Medici, Silvio Silvestri
-
Publication number: 20130089613Abstract: Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPAR?,?,?) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPAR?,?,?).Type: ApplicationFiled: June 18, 2011Publication date: April 11, 2013Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Yaping Wang, Guojun Zheng, Peng Sun, Yi Li, Yingqiu Wu, Bin Liu, Xiaoyu Liu, Hua Bai, Hongyan Li, Xiaohe Zheng
-
Publication number: 20130089610Abstract: The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.Type: ApplicationFiled: October 9, 2012Publication date: April 11, 2013Applicant: Teva Pharmaceutical Industries, Ltd.Inventor: Teva Pharmaceutical Industries, Ltd.
-
Publication number: 20130089611Abstract: The subject invention provides rasagiline citramide and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of rasagiline citramide or a salt thereof.Type: ApplicationFiled: October 9, 2012Publication date: April 11, 2013Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
-
Publication number: 20130089612Abstract: The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan.Type: ApplicationFiled: October 9, 2012Publication date: April 11, 2013Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
-
Patent number: 8399017Abstract: A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose and 10 to 12 parts by weight of colloidal silica. A non-enteric protective coating that slows down the gastric dissolution of the magnesium may comprise 15 to 75 parts by weight of shellac, cellulose ether or a mixture thereof. The tablet may be administered to patients in need thereof.Type: GrantFiled: May 20, 2009Date of Patent: March 19, 2013Inventor: Fabienne Joanny
-
Publication number: 20130034607Abstract: The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge.Type: ApplicationFiled: October 12, 2012Publication date: February 7, 2013Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventor: Mitsubishi Tanabe Pharma Corporation
-
Patent number: 8337892Abstract: The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterized in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste.Type: GrantFiled: July 25, 2000Date of Patent: December 25, 2012Assignee: ETHYPHARMInventors: Guy Couaraze, Bernard Leclerc, Pierre Tchoreloff, Patrick Sanial
-
Publication number: 20120315332Abstract: A pharmaceutical composition containing sunflower extract comprises the extract of total flavonoids from leaves, heads or stems of sunflower (Helianthus annuus L.), in which the content of total flavonoids is 50-90%. Preferably, the pharmaceutical composition comprises the extract of total terpenes and/or the extract of total organic acids. The pharmaceutical composition is used as an active ingredient in manufacture of foods, functional foods or medicaments for preventing or treating hypertension.Type: ApplicationFiled: December 28, 2009Publication date: December 13, 2012Applicant: Peixue LingInventors: Peixue Ling, Ling Zhang, Chenglei Shao, Tao Ji, Lixia Shang, Zhiping Fan
-
Patent number: 8329216Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: June 29, 2006Date of Patent: December 11, 2012Assignee: Endo Pharmaceuticals Inc.Inventors: Haui-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Publication number: 20120308653Abstract: A mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is disclosed. In more details, the conventional mugwort pill is prepared by a hot water extraction method and has 0.8% of crude fat component; however the ethanol extract mugwort crude fat of the present invention is 11.6%, in particular the crude fat component is 14.5 times higher, and the novel swine-origin influenza virus (H1N1) can be inactivated 99.99%, and it has a good disinfection effect to an avian influenza virus (H9N2). When a mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is administrated to people or fowls, the people or fowls can have immunity with respect to a novel swine-origin influenza virus and an avian influenza virus.Type: ApplicationFiled: January 31, 2011Publication date: December 6, 2012Inventors: Bongkwan Jo, Heeyoung Shim
-
Publication number: 20120308656Abstract: A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin.Type: ApplicationFiled: May 30, 2012Publication date: December 6, 2012Applicant: Wakunaga Pharmaceutical Co., Ltd.Inventors: Yukoh Sakata, Masaharu Higuchi
-
Patent number: 8309122Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: February 28, 2007Date of Patent: November 13, 2012Assignee: Endo Pharmaceuticals Inc.Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Patent number: 8309128Abstract: It is intended to provide a milnacipran formulation which is more stable than a conventionally known milnacipran formulation, and a method of stabilizing a milnacipran formulation. The object could be achieved by using a milnacipran-containing composition in which milnacipran or a salt thereof is allowed to exist in a porous carrier, packing a powder containing milnacipran or a salt thereof in an HPMC capsule, or combining an additive which does not cause an interaction with milnacipran with time.Type: GrantFiled: June 8, 2006Date of Patent: November 13, 2012Assignee: Pierre Fabre MedicamentInventors: Kazumi Suzuki, Hitoshi Yamada
-
Publication number: 20120282339Abstract: The invention relates to compositions for use in purgatives, to purgatives comprising such compositions, and to methods for inducing purgation of the colon. The composition may comprise at least one water-soluble sodium salt; at least one water-soluble minimally degradable sugar in an amount, by weight, of from about 1 to about 3 times the weight of sodium ions in said composition; at least one water-soluble potassium salt in an amount, by weight, of from about 0.05 to about 1 time the weight of said sodium salt in said composition; and at least one water-soluble magnesium salt, wherein the weight of magnesium ions in said composition is from 0.1 to about 10 times the weight of sodium ions in said composition.Type: ApplicationFiled: June 29, 2012Publication date: November 8, 2012Inventors: Thomas Julius BORODY, Sanjay RAMRAKHA, John SAXON, Anthony WETTSTEIN
-
Patent number: 8268351Abstract: A pharmaceutical matrix film tablet with controlled release of natural mixtures of conjugated estrogens which have been obtained from the urine of pregnant mares.Type: GrantFiled: June 14, 2004Date of Patent: September 18, 2012Assignee: Abbott Products GmbHInventors: Bernd Thumbeck, Klaus Budde, Gerhard Kristen, Margit Wiards
-
Publication number: 20120207833Abstract: Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: February 10, 2012Publication date: August 16, 2012Inventors: Stephan D. Parent, Lisa L. McQueen, Patricia Andres, Paul Schields, Yiduo Wu, Fei Ding, Jared P. Smit
-
Publication number: 20120183614Abstract: Provided are a polyphenol compound absorption promoter which is widely applicable to foods and drinks over a wide range, and a method for producing a food, drink or food material containing a polyphenol compound. The polyphenol compound absorption promoter comprises, as the active ingredient, at least one member selected from the group consisting of serine, aspartic acid, malic acid, capric acid, lauric acid, grapefruit juice and Camellia sinensis (L.) O. Kuntze extract. The method for producing a food, drink or food material containing a polyphenol compound comprises: adding at least one member selected from the group consisting of serine, aspartic acid, malic acid, capric acid, lauric acid, grapefruit juice and Camellia sinensis (L.) O.Type: ApplicationFiled: October 6, 2009Publication date: July 19, 2012Inventors: Koji Yanae, Shinpei Kawakami, Masatoshi Kato, Yuko Setoguchi, Masanori Sugitani
-
Publication number: 20120177738Abstract: The present invention relates to a green tea formulation stabilized by natural antioxidants such as OPC together with vitamin C or vitamin C analogs. The invention also relates to the use of a mixture of OPC and ascorbic acid to increase bioavailability of green tea catechins. It also relates to a food, pharmaceutical or cosmetic composition that contains the stabilized green tea formulation.Type: ApplicationFiled: May 28, 2010Publication date: July 12, 2012Applicant: NESTEC S.A.Inventors: Pierre Lambelet, Karlheinz Bortlik, Magalie Sabatier, Vanessa Crespy, Gary Williamson
-
Publication number: 20120156296Abstract: This invention relates to antioxidants and combinations of antioxidants used to prevent oxidation of pharmaceutical and nutraceutical products in the form of powders, granulates, tablets, emulsions, gels and the like comprising one or more fatty acids and/or fatty acid derivatives and, optionally, at least one carbohydrate carrier alone or together with vitamins, minerals and/or pharmaceuticals. In particular, the invention concerns the use of antioxidants to reduce oxidation of powders, tablets, gels and emulsions comprising high concentrations and high doses of omega-3 fatty acids or derivatives thereof.Type: ApplicationFiled: December 21, 2011Publication date: June 21, 2012Applicant: OMEGATRI ASInventors: Trine-Lise Torgersen, Jo Klaveness, Astrid Hilde Myrset
-
Publication number: 20120135078Abstract: A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may be used in combination with one or more additional therapeutic agents, such as anti-anginal agents. Pharmaceutical compositions, medicaments and kits for the treatment of angina are also described.Type: ApplicationFiled: June 1, 2010Publication date: May 31, 2012Applicant: University of DindeeInventor: Allan Struthers
-
Publication number: 20120100212Abstract: A water floatable tablet, which is either: (a) a tablet comprising at least one filler selected from the group consisting of a sugar alcohol, a sugar, a cellulose derivative, and a starch and a component which exhibits a hydrophobic effect, wherein the tablet has a hollow cavity in a center section; or (b) a tablet obtained by a process including: (1) forming a crust comprising at least one filler selected from the group consisting of a sugar alcohol, a sugar, a cellulose derivative, and a starch on an outer surface of a core comprising a sublimation solid, to obtain a dry coated tablet having the core positioned at a center section; (2) heating the dry coated tablet, to obtain a tablet having a hollow cavity; and (3) contacting the tablet having a hollow cavity with a component which exhibits a hydrophobic effect.Type: ApplicationFiled: July 5, 2010Publication date: April 26, 2012Applicant: KYORIN PHARMACEUTICAL, CO., LTD.Inventors: Mamoru Fukuda, Akinori Goto
-
Publication number: 20120093926Abstract: The invention relates to a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the release of the pharmaceutical or nutraceutical active ingredient is not more than 15% under in-vitro conditions at pH 1.Type: ApplicationFiled: April 13, 2011Publication date: April 19, 2012Applicant: Evonik Roehm GmbHInventors: Shraddha Ashok Bodinge, Priyanka Bansilal Haksar, Seema Yashwant Gawde, Hemant Karbhari Pagar, Hans-Ulrich Petereit
-
Publication number: 20120082723Abstract: It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20° C. of 30 or more.Type: ApplicationFiled: September 30, 2011Publication date: April 5, 2012Inventors: Yumio Kudou, Kuniomi Warabino
-
Publication number: 20120076857Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: September 6, 2011Publication date: March 29, 2012Applicant: SALIX PHARMACEUTICALS, LTD.Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20120070497Abstract: Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-?-boswellic acid, 11-keto-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 9,11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof, a pharmaceutically acceptable salt thereof, a combination thereof, or a preparation containing one or more of these compounds) for the human medical or veterinary prophylaxis and/or treatment of: a) damage to and/or inflammation of the islets of Langerhans and/or b) damage to the B-cells of the islets of Langerhans.Type: ApplicationFiled: September 22, 2011Publication date: March 22, 2012Applicant: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.Inventor: Hermann P.T. Ammon
-
Publication number: 20120058185Abstract: The present invention provides a stable pharmaceutical composition of Olanzapine or its pharmaceutically acceptable salt comprising coated tablet formulations of Olanzapine or its pharmaceutically acceptable salt, wherein the coating consists essentially of pectin or copovidone, and a process of making the same.Type: ApplicationFiled: May 20, 2010Publication date: March 8, 2012Inventors: Pattanayak Durgaprasad, Tallam Satyanarayana, V Satyanarayana, Rampal Ashok
-
Publication number: 20110305759Abstract: A white colouring composition comprising calcium carbonate as a white pigment. It may be used in the manufacture of food and pharmaceutical products.Type: ApplicationFiled: December 28, 2009Publication date: December 15, 2011Inventor: Klaus Koehler
-
Patent number: 8076279Abstract: The present invention is related to the use of a non-cellulosic cationically modified polysaccharide in cleaning compositions and more particularly to a surfactant based cleansing composition comprising, a surfactant, a non-cellulosic cationically modified polysaccharide and a solvent for use in personal care composition, household care composition or an institutional care composition.Type: GrantFiled: October 9, 2009Date of Patent: December 13, 2011Assignee: Hercules IncorporatedInventors: Piet Brand, Richard G. Brown, Anita N. Chan, Paquita Erazo-Majewicz, Jashawant J. Modi
-
Publication number: 20110274753Abstract: Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.Type: ApplicationFiled: May 5, 2011Publication date: November 10, 2011Applicant: Sanovel Ilac Sanayi Ve Ticaret Anonim SirketiInventors: Umit Cifter, Ali Turkyilmaz, Ibrahim Murat Uzer, Alper Terkinli, Levent Oner
-
Publication number: 20110244041Abstract: The invention relates to a hydrolyzate from at least one extract of at least one plant material selected from the group consisting of at least one genus: Equiseti, Juglandis, Millefolii, Quercus, Taraxaci, Althaeae, Matricariae, Centaurium, Levisticum, Rosmarinus, Angelica(e), Artemisia, Astragalus, Leonurus, Salvia, Saposhnikovia, Scutellaria, Siegesbeckia, Armoracia, Capsicum, Cistus, Echinacea, Echinacea, Galphimia, Hedera, Melia, Olea, Pelargonium, Phytolacca, Primula, Salix, Thymus, Vitex, and Vitis; and to a mixture thereof and to a method of production and the use thereof. The invention further relates to an agent and drug obtainable on the basis of the hydrolyzate.Type: ApplicationFiled: November 2, 2009Publication date: October 6, 2011Applicant: BIONORICA SEInventor: Michael A. Popp
-
Patent number: 8029825Abstract: The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.Type: GrantFiled: November 10, 2004Date of Patent: October 4, 2011Assignee: EthypharmInventors: Pierre Tchoreloff, Bernard Leclerc, Guillaume Benoist, Laurent Bertocchi
-
Publication number: 20110195102Abstract: Peptides with general formula (I): R1-AA1-AA2-AA3-AA4-R2 its stereoisomers, mixtures thereof, and its cosmetically or pharmaceutically acceptable saits, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment and/or care of conditions, disorders and/or pathologies of the skin, mucous membranes, scalp and/or hair.Type: ApplicationFiled: October 2, 2009Publication date: August 11, 2011Applicant: LIPOTEC, S.A.Inventors: Wim Van Den NestT, Nuria Almiñana Domenech, Juan Cebrian Puche, Cristina Carreño Serraïma
-
Publication number: 20110150992Abstract: Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo.Type: ApplicationFiled: December 17, 2010Publication date: June 23, 2011Inventors: Kristin Arnold, Matthew W. Davis, Suman Wason, Siva Rama K. Nutalapati
-
Publication number: 20110111026Abstract: The invention relates to a pharmaceutical composition of a humidity-sensitive core comprising an active ingredient or pharmaceutically acceptable salt thereof; a coating over the core, the coating containing a cationic polymer; and an additional coating over the cationic polymer-containing coating, with the additional coating including an acidifying agent. Also, methods for preparing such compositions wherein a cationic polymer containing coating is applied over a humidity-sensitive core that contains the active ingredient or pharmaceutically acceptable salt thereof; and then an additional coating is applied over the cationic polymer containing coating.Type: ApplicationFiled: March 10, 2009Publication date: May 12, 2011Inventors: Adel Penhasi, Yaakov Stephane Attali
-
Publication number: 20110097401Abstract: Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.Type: ApplicationFiled: June 11, 2010Publication date: April 28, 2011Applicant: MERITAGE PHARMA, INC.Inventors: Elaine Phillips, Malcolm Hill, Adam Simpson
-
Patent number: 7927625Abstract: A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar coating layer, and a middle layer that includes a film component and a sugar coating component and is provided between the film layer and the sugar coating layer, wherein within the middle layer, the concentration of the sugar coating component at the interface between the middle layer and the sugar coating layer is higher than the concentration of the sugar coating component at the interface between the middle layer and the film layer.Type: GrantFiled: March 9, 2006Date of Patent: April 19, 2011Assignee: Taisho Pharmaceutical Co., LtdInventors: Junichi Kishimoto, Reiko Tanaka
-
Patent number: 7928111Abstract: The present invention provides compounds including substituted thienopyrimidinone derivatives of Formula (IIc) as ligands for modulating chemosensory receptors: These compounds are useful as sweet taste enhancers in comestible or medicinal compositions. The present invention also provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.Type: GrantFiled: August 8, 2007Date of Patent: April 19, 2011Assignee: Senomyx, Inc.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Publication number: 20110033526Abstract: The invention relates to medicine and pharmacology, in particular to pharmaceutical compositions containing the following antimicrobial preparations: antibiotics and sulphanylamides combined with prebiotic in the form of a lactulose. The composition is used for preventing enteral dysbiosis arising during antibiotic therapy using the wide range of preparations. The inventive pharmaceutical composition contains antibiotic or a sulphanylamide preparation and lactulose, wherein the antibiotic particle size ranges from 20 to 160 mkm, the sulphanylamide preparation particle size ranges from 40 to 150 mkm and the lactulose has a particle size equal to or less than 0.3 mm and the purity of at least 97%, with the ratio of the antibiotic and lactulose ranging from 1:0.1 to 1:100, and the ratio of the sulphanylamide preparation and lactulose of 1:12, said composition being internally administered.Type: ApplicationFiled: March 18, 2008Publication date: February 10, 2011Inventors: Aleksander Vladimirovich Dikovskiy, Oleg Valentinovich Dorozhko, Boris Anatolievich Rudoi